Anuh Pharma Ltd
Anuh Pharma Q1 FY23 earnings call: Revenue & Margins
Q1 FY23 investor presentation: what the company reported on revenue, margins and projects.
Based on Anuh Pharma Ltd's Q1 FY23 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1 FY23 Operating Revenue: Rs. Q1 FY23 EBITDA: Rs.
From Anuh Pharma Ltd's Q1 FY23 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 FY23 Operating Revenue: Rs. 116.38 Cr, down 1% YoY from Rs. 117.27 Cr in Q1 FY22 (Page 14, 13)
- Domestic Sales Contribution: 61% in Q1 FY23 (up from 49% in Q1 FY22) (Page 9)
- Export Sales Contribution: 39% in Q1 FY23 (down from 51% in Q1 FY22) (Page 9)
- Export sales increased by 50% compared to Q1 FY22 (Page 6)
- Volume trends: Not explicitly stated in numbers, but demand from exports up by 50% and domestic subdued in Q1 FY23 (Page 6)
- Outlook:
- Expect upswing in demand from next quarters, driven by anti-malarial, corticosteroids, diabetic, and expectorant segments (Page 6)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Enhanced manufacturing capacity at L&L site for corticosteroids increased to 12 MTPA.
- New plant in Tarapur (capacity 1500 MT) commenced in 2019; used for higher market share in Sulfadoxine, Ambroxol HCl, Gliclazide, and new product launches.
- No specific capex amounts or future timelines explicitly mentioned for new plants/projects in the presentation.
- Focus on efficiency improvements, yield, throughput, and solvent recoveries ongoing, but no quantified capex or timelines detailed.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Anuh Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹202 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anuh Pharma Ltd's management said in earlier quarters
Frequently Asked Questions
What were Anuh Pharma Ltd Q1 FY23 results?
Q1 FY23 Operating Revenue: Rs. Q1 FY23 EBITDA: Rs.
What is Anuh Pharma Ltd share price analysis?
Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anuh Pharma Ltd planning capital expenditure?
Enhanced manufacturing capacity at L&L site for corticosteroids increased to 12 MTPA.
Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.